Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	291.96B
Revenue (ttm)	155.49B
Net Income (ttm)	19.68B
Shares Out	70.30M
EPS (ttm)	270.21
PE Ratio	15.37
Forward PE	15.84
Dividend	90.00 (2.17%)
Ex-Dividend Date	Feb 26, 2026

Volume	138,100
Average Volume	146,230
Open	4,150.00
Previous Close	4,166.00
Day's Range	4,138.00 - 4,184.00
52-Week Range	3,783.00 - 4,735.00
Beta	0.15
RSI	48.72
Earnings Date	Jan 6, 2026

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.